BPX-601 is under clinical development by Bellicum Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BPX-601’s likelihood of approval (LoA) and phase transition for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer took place on 30 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BPX-601 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BPX-601 is under development for the treatment of solid tumors including prostate cancer, gastro esophageal junction carcinoma, metastatic gastric cancer and hormone-refractory prostate cancer. It is administered through intravenous (infusion) route. The therapy is composed of retroviral vector transduced CAR T cells that target prostate stem cell antigen (PSCA) and rimiducid. The drug candidate is based on the GoCAR-T technology. The technology includes proprietary inducible MyD88/CD40 (iMC) activation switch, to enable control of the activation and proliferation of the T cells through the scheduled administration of a course of rimiducid infusions. It was also under development for the treatment of leukemia and metastatic pancreatic cancer.
Bellicum Pharmaceuticals overview
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products for the treatment of solid tumors, hematological cancers and others. Bellicum is headquartered in Houston, Texas, the US.
Quick View BPX-601 LOA Data
|Highest Development Stage|